 Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Efficacy and safety of PARPi Veliparib combined with carboplatin and etoposide in the treatment of advanced small cell lung cancer

Clin Cancer Res: Efficacy and safety of PARPi Veliparib combined with carboplatin and etoposide in the treatment of advanced small cell lung cancer

 Last Update: 2021-08-03
 Source: Internet
 Author: User

Tags

pvc cancer

small plastic

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Small cell lung cancer (SCLC) is a neuroendocrine cancer characterized by aggressive behavior, rapid cell division, and early metastasis, accounting for about 15% of lung cancers
.
This study aims to investigate the efficacy and safety of oral PARP inhibitor Veliparib combined with carboplatin and etoposide in patients with newly treated, advanced small cell lung cancer (ED-SCLC)

Small cell lung cancer (SCLC) is a neuroendocrine cancer characterized by aggressive behavior, rapid cell division and early metastasis, accounting for about 15% of lung cancers

The test patients were randomly divided into three groups 1:1:1, and received Veliparib (240 mg·2 times/day [BID] for 14 days) combined with chemotherapy, followed by Veliparib maintenance (400 mg BID;); Veliparib combined Chemotherapy followed by placebo; or placebo combined with chemotherapy followed by chemotherapy (control)
.
After 4-6 courses of combined therapy, patients were switched to maintenance therapy until unacceptable toxicity/progress appeared

PFS and OS of all randomized patients

In total, a total of 181 patients were recruited: 61 in the Veliparib penetration treatment group, 59 in the Veliparib combined treatment group, and 61 in the control group
.
Compared with the control group, the PFS of Veliparib throughout the treatment group was significantly prolonged : the median PFS was 5.

8 months and 5.

Compared with the control group, the PFS of the Veliparib penetration treatment group was significantly prolonged.

PFS in SLFN11-positive (A) and SLFN11-negative (B) patients

The incidence of grade 3/4 adverse events in the Veliparib through-treatment group, Veliparib-only combined treatment group, and control group were 82%, 88%, and 68%, respectively.

In summary, Veliparib combined with platinum chemotherapy followed by Veliparib maintenance, as a first-line therapy, can improve the PFS of ED-SCLC patients, and the safety is acceptable , but there is no corresponding benefit in OS

Veliparib combined with platinum chemotherapy followed by Veliparib as a first-line therapy can improve the PFS of ED-SCLC patients, and the safety can be maintained by Veliparib combined with platinum chemotherapy followed by Veliparib, as a first-line therapy can improve the PFS of ED-SCLC patients, and its safety Acceptable

Original source:

Lauren Averett Byers, et al.

Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naive Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.